keyword
MENU ▼
Read by QxMD icon Read
search

Zoledronic acid

keyword
https://www.readbyqxmd.com/read/29137420/anti-angiogenic-and-anti-tumor-effects-of-metronomic-use-of-novel-liposomal-zoledronic-acid-depletes-tumor-associated-macrophages-in-triple-negative-breast-cancer
#1
Xin-Jun Cai, Zeng Wang, Jia-Wei Cao, Jian-Jun Ni, Ying-Ying Xu, Jun Yao, Hong Xu, Fang Liu, Gao-Yi Yang
Zoledronic acid (ZOL) has been used as an adjuvant therapy for breast cancer. It is suggested that ZOL might be associated with inhibition of macrophages, which in turn reduces tumor growth, metastasis and tumor angiogenesis. Moreover, metronomic therapy can inhibit tumor angiogenesis and tumor immune cells. Previously we developed ZOL based cationic liposomes that allowed a higher intratumor delivery of drug compared with free ZOL in vivo. Therefore, in this study, Asn-Gly-Arg (NGR) and PEG2000 were used as ligands to modify the surface of liposomes (NGR-PEG-LP-ZOL) in metronomic therapy to clear the tumor-associated macrophages (TAMs) and inhibit the formation of tumor angiogenesis, achieving the purpose of anti-tumor growth...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29132335/topical-zoledronic-acid-decreases-micromotion-induced-bone-resorption-in-a-sheep-arthroplasty-model
#2
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek
BACKGROUND: Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion. Bisphosphonates compounds are inhibitors of bone resorption. The aim of this study was to investigate whether local treatment with bisphosphonate would reduce bone resorption and fibrous tissue around an experimental implant subjected to micromotion. METHODS: One micromotion implant were inserted into each medial femoral condyle in ten sheep...
November 13, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29130610/the-effects-of-icariin-on-wound-healing-of-extraction-sites-with-administration-of-zoledronic-and-dexamethasone-a-rat-model-study
#3
Jie Liu, Nikos Mattheos, Cheng Su, Chuanxi Deng, Nanyu Luo, Zekun Wang, Hua Tang
OBJECTIVE: This study was intended to investigate the effects of Icariin on the healing of tooth extraction sites under systemic administration of Zoledronic and Dexamethasone. METHOD: Thirty female rats underwent bilateral ovariectomy and were randomly assigned to 5 groups: SS group received weekly injection of saline while ZD, ZD+LICA, ZD+MICA and ZD+HICA groups received Zoledronic with Dexamethasone for 8 weeks. One week later, mandibular first molars were extracted in all groups...
November 11, 2017: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/29125130/acid-sphingomyelinase-inhibitors-imipramine-and-zoledronic-acid-increase-skeletal-muscle-tissue-sensitivity-to-insulin-action-at-old-age
#4
Loay Kh M Hassouneh, Olga A Timofiychuk, Nataliya A Babenko
Malfunction of skeletal muscles and dysregulated turnover of sphingolipids in the insulin responsive tissues have been determined at old age. Present article investigates the role of acid sphingomyelinase (SMase)-dependent ceramide accumulation in reduction of the skeletal muscle sensitivity to insulin action at old age. The 3-, 12- and 24-month-old Wistar male rats were used in the experiments. The progressive increase of ceramide content and ceramide/sphingomyeline (SM) ratio was determined in the extensor digitorum longus (EDL) muscle during aging of rats...
November 10, 2017: General Physiology and Biophysics
https://www.readbyqxmd.com/read/29125079/-relapse-of-chronic-inflammatory-demyelinating-polyneuropathy-following-treatment-with-zoledronic-acid
#5
M Loef, E C T Geijteman, K J Beelen, M Bornebroek, D H Schweitzer
BACKGROUND: Zoledronic acid is a nitrogen-containing bisphosphonate that is frequently used in the treatment of osteoporosis. Many patients experience a so-called acute-phase reaction during initial treatment; this is characterized by flu-like symptoms and fever. CASE DESCRIPTION: We describe a 61-year-old woman who suffered from chronic inflammatory demyelinating polyneuropathy (CIDP), and who was started on intravenous zoledronic acid treatment as adjuvant therapy for breast cancer...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29123990/the-skeletal-related-events-of-denosumab-versus-zoledronic-acid-in-patients-with-bone-metastases-a-meta-analysis-of-randomized-controlled-trials
#6
Zhicai Zhang, Feifei Pu, Zengwu Shao
Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29114907/effect-of-zoledronic-acid-therapy-on-postmenopausal-osteoporosis-between-the-uighur-and-han-population-in-xinjiang-an-open-label-long-term-safety-and-efficacy-study
#7
W Xu, C Xiang, H Wang, H Yuan, X Zhao, X Xiao
WHAT IS KNOWN AND OBJECTIVE: Postmenopausal osteoporosis is becoming an urgent health problem in China. A once-yearly infusion of zoledronic acid can be very effective for the treatment of postmenopausal osteoporosis in significantly reducing the risk of hip, vertebral and other fractures. This study aimed to investigate zoledronic acid treatment on postmenopausal osteoporosis in Uighur and Han patients in Xinjiang province, China. METHODS: A self-controlled and prospective trial design was adopted...
November 7, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29113188/zoledronic-acid-sensitizes-rhabdomyosarcoma-cells-to-cytolysis-mediated-by-human-%C3%AE-%C3%AE-t-cells
#8
Ling-Ling Sun, Zheng-Liang Zhang, Ying-Jun Li, Sheng-Dong Wang, Heng-Yuan Li, Bing-Hao Li, Ting Zhu, Zhao-Ming Ye
Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children. Immunotherapy has been proposed as a treatment for this deadly tumor. In the present study, the cytotoxicity of ex vivo expanded γδ T cells on RMS cell lines was evaluated and the molecular interactions involved were investigated. γδ T cells were expanded in vitro using peripheral blood mononuclear cells from 5 healthy donors and were stimulated with zoledronic acid (Zol) and interleukin 2. RMS cell lines RD and A-673 were used as target cells...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29109954/role-of-periapical-diseases-in-medication-related-osteonecrosis-of-the-jaws
#9
Nian Jing Rao, Jing Yi Wang, Ru Qing Yu, Yiu Yan Leung, Li Wu Zheng
Objective: The present study aimed to investigate the role of periapical diseases in inducing medication-related osteonecrosis of the jaws (MRONJ) using an ovariectomized (OVX) mice model. Materials and Methods: Twenty C57BL/6N female mice were randomly assigned to two groups. All mice were subjected to bilateral ovariectomy and then treated with oncologic dose of zoledronic acid (ZA) or vehicle for twelve weeks. Eight weeks after commence of drug administration, a pulpal exposure (PE) operation was performed on the first right lower molar to induce periapical periodontitis; the contralateral non-PE tooth was used as control...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29081061/zoledronic-acid-bevacizumab-and-dexamethasone-induced-apoptosis-mitochondrial-oxidative-stress-and-calcium-signaling-are-decreased-in-human-osteoblast-like-cell-line-by-selenium-treatment
#10
Tayfun Yazıcı, Gülperi Koçer, Mustafa Nazıroğlu, İshak Suat Övey, Ahmi Öz
Increased intracellular free calcium ion (Ca(2+)) concentration induces excessive oxidative stress and apoptosis. Medical procedures such as zoledronic acid (Zol), bevacizumab (Bev), and dexamethasone (Dex) are usually used in the treatment of bone diseases (osteoporosis, Paget's disease, etc.) and to prevent metastasis in the bone although the procedures induce osteonecrosis of the jaw through excessive production of reactive oxygen species (ROS). Recently, we observed regulator roles of selenium (Se) on apoptosis and Ca(2+) entry through transient receptor potential vanilloid 1 (TRPV1) channels in the cancer cell lines...
October 28, 2017: Biological Trace Element Research
https://www.readbyqxmd.com/read/29079514/dual-modulation-of-bone-formation-and-resorption-with-zoledronic-acid-loaded-biodegradable-magnesium-alloy-implants-improves-osteoporotic-fracture-healing-an-in-vitro-and-in-vivo-study
#11
Guoyuan Li, Lei Zhang, Lei Wang, Guangyin Yuan, Kerong Dai, Jia Pei, Yongqiang Hao
Osteoporotic fracture (OPF) remains a major clinical challenge for skeletal regeneration. Impaired osteogenesis and excessive remodeling result in prolonged and poor quality of fracture healing. To augment bone formation and inhibit excessive resorption simultaneously, we constructed a biodegradable magnesium-based implant integrated with the anti-catabolic drug zoledronic acid (ZA); this implant exhibits controllable, sustained release of magnesium degradation products and ZA in vitro. The extracts greatly stimulate the osteogenic differentiation of rat-bone marrow-derived mesenchymal stem cells (rBMSCs), while osteoclastogenesis is inhibited by ZA...
October 24, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/29073497/therapeutic-approaches-for-protecting-bone-health-in-patients-with-breast-cancer
#12
REVIEW
Diana Lüftner, Daniela Niepel, Guenther G Steger
Improvements in the survival of patients with breast cancer, together with a better understanding of the pathology of the disease, have led to the emergence of bone health as a key aspect of patient management. Patients with breast cancer are typically at risk of skeletal complications throughout their disease course. The receptor activator of nuclear factor κ B ligand (RANKL) inhibitor denosumab and bisphosphonates (e.g. zoledronic acid) are approved in Europe for the prevention of skeletal-related events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) in adults with bone metastases secondary to solid tumours...
October 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29069999/use-of-hormone-therapies-in-disseminated-carcinomatosis-of-the-bone-marrow-associated-with-hormone-receptor-positive-breast-cancer
#13
Takayo Ota, Nozomi Miyatake, Noriko Tanaka, Yoshikazu Hasegawa, Masahiro Tokunaga, Hiroshi Tsukuda, Masahiro Fukuoka
Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM...
October 26, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29068481/hypophosphatemia-severe-bone-pain-gait-disturbance-and-fatigue-fractures-after-iron-substitution-in-inflammatory-bowel-disease-a-case-report
#14
J Bartko, P Roschger, S Zandieh, A Brehm, J Zwerina, K Klaushofer
Intravenous infusions of different iron formulations are recognized as a cause of hypophosphatemia. Chronic hypophosphatemia can alter bone metabolism and bone material structure. As a consequence, osteomalacia may develop and lead to bone fragility. Herein, we report a patient with Crohn's disease presenting with persistent hypophosphatemia and insufficiency fractures while receiving regular iron infusions due to chronic gastrointestinal bleeding. Previously, the patient received regularly vitamin D and also zoledronic acid...
October 25, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29063388/utilization-of-agents-to-prevent-skeletal-related-events-among-patients-with-multiple-myeloma-analysis-of-real-world-data
#15
Yi Qian, Debajyoti Bhowmik, Nandita Kachru, Rohini K Hernandez, Paul Cheng, Alexander Liede
PURPOSE: This study examined real-world utilization patterns of bone-targeted agents (BTA) in patients with multiple myeloma (MM). METHODS: In this retrospective cohort study, adults with an MM diagnosis recorded in 2012-2014 were identified from electronic health records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients received zoledronic acid (ZA) or pamidronate (PA) on/after first MM diagnosis recorded in the study period, had no BTA use in prior 6 months, and were followed through earliest of May 31, 2015 or last clinic visit...
October 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29052442/denosumab-for-the-treatment-of-bone-disease-in-solid-tumors-and-multiple-myeloma
#16
Andrew J Yee, Noopur S Raje
Bone is a common site for malignant involvement, either as a site of metastasis, especially in breast or prostate cancer, or as a defining characteristic of the disease, as in multiple myeloma. Bone disease is a major source of morbidity, and half of patients with bone involvement develop skeletal-related events such as pathological fractures or cord compression requiring surgery and/or radiation. Skeletal involvement also increases mortality, as pathologic fractures increase the risk of dying by 20-40%. Osteoclast inhibition with bisphosphonates such as zoledronic acid and recently denosumab has been a significant improvement for bone disease...
October 20, 2017: Future Oncology
https://www.readbyqxmd.com/read/29037985/adjuvant-zoledronic-acid-to-treat-breast-cancer-not-for-all
#17
Luís Costa, Arlindo R Ferreira
No abstract text is available yet for this article.
October 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29037984/effect-of-maf-amplification-on-treatment-outcomes-with-adjuvant-zoledronic-acid-in-early-breast-cancer-a-secondary-analysis-of-the-international-open-label-randomised-controlled-phase-3-azure-big-01-04-trial
#18
Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Joël Jean-Mairet, Juan-Carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis
BACKGROUND: Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid. METHODS: The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples...
October 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29035643/role-of-bone-modifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update
#19
Catherine Van Poznak, Mark R Somerfield, William E Barlow, J Sybil Biermann, Linda D Bosserman, Mark J Clemons, Sukhbinder K Dhesy-Thind, Melissa S Dillmon, Andrea Eisen, Elizabeth S Frank, Reshma Jagsi, Rachel Jimenez, Richard L Theriault, Theodore A Vandenberg, Gary C Yee, Beverly Moy
Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases...
October 16, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29035507/sequential-delivery-of-doxorubicin-and-zoledronic-acid-to-breast-cancer-cells-by-cb-7-modified-iron-oxide-nanoparticles
#20
Farah Benyettou, Marwa Alhashimi, Matthew O'Connor, Renu Pasricha, Jeremy Brandel, Hassan Traboulsi, Javed Mazher, John-Carl Olsen, Ali Trabolsi
Drug-loaded magnetic nanoparticles were synthesized and used for the sequential delivery of the antiresorptive agent zoledronic acid (Zol) and the cytotoxic drug doxorubicin (Dox) to breast cancer cells (MCF-7). Zol was attached to bare iron oxide nanoparticles (IONPs) via phosphonate coordination to form Z-NPs. The unbound imidazole of Zol was then used to complex the organic macrocycle CB[7] to obtain CZ-NPs. Dox was complexed to the CZ-NPs to form the fully loaded particles (DCZ-NPs), which were stable in solution at 37 °C and physiological pH (7...
November 7, 2017: ACS Applied Materials & Interfaces
keyword
keyword
27337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"